CN101801989A - 用于制备钠-葡萄糖协同转运蛋白2抑制剂的方法和化合物 - Google Patents
用于制备钠-葡萄糖协同转运蛋白2抑制剂的方法和化合物 Download PDFInfo
- Publication number
- CN101801989A CN101801989A CN200880100489A CN200880100489A CN101801989A CN 101801989 A CN101801989 A CN 101801989A CN 200880100489 A CN200880100489 A CN 200880100489A CN 200880100489 A CN200880100489 A CN 200880100489A CN 101801989 A CN101801989 A CN 101801989A
- Authority
- CN
- China
- Prior art keywords
- compound
- formula
- alkyl
- acid
- independently
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H5/00—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium
- C07H5/04—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium to nitrogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/02—Acyclic radicals, not substituted by cyclic structures
- C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
- C07H7/04—Carbocyclic radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H9/00—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical
- C07H9/02—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical the hetero ring containing only oxygen as ring hetero atoms
- C07H9/04—Cyclic acetals
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Diabetes (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Crystallography & Structural Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrane Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Saccharide Compounds (AREA)
- Peptides Or Proteins (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims (99)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US95212207P | 2007-07-26 | 2007-07-26 | |
US60/952,122 | 2007-07-26 | ||
PCT/US2008/070250 WO2009014970A1 (en) | 2007-07-26 | 2008-07-17 | Methods and compounds useful for the preparation of sodium glucose co-transporter 2 inhibitors |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101801989A true CN101801989A (zh) | 2010-08-11 |
CN101801989B CN101801989B (zh) | 2015-11-25 |
Family
ID=39877996
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN200880100489.2A Active CN101801989B (zh) | 2007-07-26 | 2008-07-17 | 用于制备钠-葡萄糖协同转运蛋白2抑制剂的方法和化合物 |
Country Status (25)
Country | Link |
---|---|
US (2) | US8026347B2 (zh) |
EP (1) | EP2183263B1 (zh) |
JP (2) | JP5653213B2 (zh) |
KR (1) | KR101663324B1 (zh) |
CN (1) | CN101801989B (zh) |
AR (2) | AR067701A1 (zh) |
AT (1) | ATE530558T1 (zh) |
AU (1) | AU2008279424B2 (zh) |
BR (1) | BRPI0813840A2 (zh) |
CA (1) | CA2694029C (zh) |
CL (1) | CL2008002169A1 (zh) |
CO (1) | CO6260141A2 (zh) |
DK (1) | DK2183263T3 (zh) |
EA (1) | EA017411B1 (zh) |
EC (1) | ECSP109987A (zh) |
ES (1) | ES2375800T3 (zh) |
HK (1) | HK1143982A1 (zh) |
IL (1) | IL203209A (zh) |
NZ (1) | NZ582536A (zh) |
PL (1) | PL2183263T3 (zh) |
PT (1) | PT2183263E (zh) |
TW (2) | TWI419886B (zh) |
UA (1) | UA107175C2 (zh) |
WO (1) | WO2009014970A1 (zh) |
ZA (1) | ZA201000219B (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104854096A (zh) * | 2012-11-20 | 2015-08-19 | 莱西肯医药有限公司 | 钠葡萄糖协同转运蛋白1的抑制剂 |
CN109476624A (zh) * | 2016-05-28 | 2019-03-15 | 海南轩竹医药科技有限公司 | 钠-葡萄糖协同转运蛋白2抑制剂的晶型 |
CN110818722A (zh) * | 2018-08-14 | 2020-02-21 | 苏州鹏旭医药科技有限公司 | 三种化合物及其制备方法和在合成索格列净中的用途 |
CN113880701A (zh) * | 2021-10-10 | 2022-01-04 | 浙江司太立制药股份有限公司 | 一种抗糖尿病药物中间体及其制备方法 |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI499414B (zh) | 2006-09-29 | 2015-09-11 | Lexicon Pharmaceuticals Inc | 鈉與葡萄糖第2型共同運輸體(co-transporter 2)的抑制物與其應用方法 |
MX2011000637A (es) | 2008-07-15 | 2011-05-02 | Theracos Inc | Derivados deuretados de bencilbenceno y metodos de uso. |
TWI472521B (zh) * | 2008-07-17 | 2015-02-11 | Lexicon Pharmaceuticals Inc | (2s,3r,4r,5s,6r)-2-(4-氯-3-(4-乙氧苄基)苯基)-6-(甲硫)四氫-2h-哌喃-3,4,5-三醇的固體形態與其使用方法 |
BRPI0918841B8 (pt) | 2008-08-28 | 2021-05-25 | Pfizer | derivados de dioxa-biciclo[3.2.1]octano-2,3,4-triol, seus cristais, composições farmacêuticas e usos |
ME02016B (me) | 2009-11-02 | 2015-05-20 | Pfizer | Derivati dioksabiciklo[3.2.1]oktan-2,3,4-triola |
RU2564901C2 (ru) | 2009-11-13 | 2015-10-10 | Бристол-Майерс Сквибб Кампани | Композиции метформина с уменьшенной массой |
CA2780939C (en) | 2009-11-13 | 2018-06-12 | Bristol-Myers Squibb Company | Bilayer tablet formulations |
RS57926B1 (sr) | 2009-11-13 | 2019-01-31 | Astrazeneca Ab | Formulacije tablete sa trenutnim oslobađanjem |
TWI562775B (en) * | 2010-03-02 | 2016-12-21 | Lexicon Pharmaceuticals Inc | Methods of using inhibitors of sodium-glucose cotransporters 1 and 2 |
WO2011153712A1 (en) * | 2010-06-12 | 2011-12-15 | Theracos, Inc. | Crystalline form of benzylbenzene sglt2 inhibitor |
CN103370064A (zh) | 2010-09-03 | 2013-10-23 | 百时美施贵宝公司 | 使用水溶性抗氧化剂的药物制剂 |
MX2013008372A (es) | 2011-02-01 | 2013-08-12 | Astrazeneca Uk Ltd | Formulaciones farmaceuticas que incluyen compuesto de amina. |
KR101576589B1 (ko) | 2011-06-01 | 2015-12-10 | 주식회사 녹십자 | Sglt2 억제제로서의 신규한 다이페닐메탄 유도체 |
BR112013031032A2 (pt) | 2011-06-03 | 2016-11-29 | Boehringer Ingelheim Int | inibidores de sglt-2 para o tratamento de distúrbios metabólicos em pacientes tratados com agentes neurolépticos |
US9193751B2 (en) | 2012-04-10 | 2015-11-24 | Theracos, Inc. | Process for the preparation of benzylbenzene SGLT2 inhibitors |
ES2959444T3 (es) | 2013-04-04 | 2024-02-26 | Boehringer Ingelheim Vetmedica Gmbh | Tratamiento de trastornos metabólicos en animales equinos |
EP2895490B1 (en) | 2013-09-27 | 2016-10-19 | Sunshine Lake Pharma Co., Ltd. | Glucopyranosyl derivatives and their uses in medicine |
CN105611920B (zh) | 2013-10-12 | 2021-07-16 | 泰拉科斯萨普有限责任公司 | 羟基-二苯甲烷衍生物的制备 |
EP4285995A3 (en) | 2013-12-17 | 2024-02-28 | Boehringer Ingelheim Vetmedica GmbH | An sglt-2 inhibitor for use in the treatment of a metabolic disorder in feline animals |
KR20220097538A (ko) | 2014-01-23 | 2022-07-07 | 베링거잉겔하임베트메디카게엠베하 | 개과 동물에서 대사 장애의 치료 |
NZ723781A (en) | 2014-04-01 | 2022-09-30 | Boehringer Ingelheim Vetmedica Gmbh | Treatment of metabolic disorders in equine animals |
EP3466958B1 (en) * | 2016-05-25 | 2020-04-29 | Crystal Pharmaceutical (Suzhou) Co., Ltd. | New crystal forms of sodium-glucose co-transporter inhibitor, processes for preparation and use thereof |
AU2017285813B2 (en) | 2016-06-17 | 2020-02-06 | Daewoong Pharmaceutical Co., Ltd. | Method for producing diphenylmethane derivative |
JP2019531320A (ja) | 2016-10-19 | 2019-10-31 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ssao/vap−1阻害剤とsglt2阻害剤とを含む組合せ、その使用 |
CN107540685B (zh) * | 2017-09-04 | 2020-05-05 | 杭州科巢生物科技有限公司 | 一种Sotagliflozin的制备方法及其中间体 |
US20210113561A1 (en) | 2018-04-17 | 2021-04-22 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
CN108675976B (zh) * | 2018-05-14 | 2020-07-14 | 浙江宏元药业股份有限公司 | 一种6-卤代葡萄糖碳苷及其制备方法和应用 |
PE20211206A1 (es) | 2018-08-13 | 2021-07-05 | Dae Woong Pharma | Preparacion de intermedio util para la sintesis de inhibidor de sglt |
US11759474B2 (en) | 2019-11-28 | 2023-09-19 | Boehringer Ingelheim Vetmedica Gmbh | Use of SGLT-2 inhibitors in the drying-off of non-human mammals |
AU2021222297A1 (en) | 2020-02-17 | 2022-08-04 | Boehringer Ingelheim Vetmedica Gmbh | Use of SGLT-2 inhibitors for the prevention and/or treatment of cardiac diseases in felines |
WO2023006718A1 (en) | 2021-07-28 | 2023-02-02 | Boehringer Ingelheim Vetmedica Gmbh | Use of sglt-2 inhibitors for the prevention and/or treatment of cardiac diseases in non-human mammals excluding felines, in particular canines |
EP4376819A1 (en) | 2021-07-28 | 2024-06-05 | Boehringer Ingelheim Vetmedica GmbH | Use of sglt-2 inhibitors for the prevention and/or treatment of hypertension in non-human mammals |
CA3224673A1 (en) | 2021-07-28 | 2023-02-02 | Boehringer Ingelheim Vetmedica Gmbh | Use of sglt-2 inhibitors for the prevention and/or treatment of renal diseases in non-human mammals |
US20230381101A1 (en) | 2022-05-25 | 2023-11-30 | Boehringer Ingelheim Vetmedica Gmbh | Aqueous pharmaceutical compositions comprising sglt-2 inhibitors |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1653075A (zh) * | 2002-05-20 | 2005-08-10 | 百时美施贵宝公司 | C-芳基葡糖苷sglt2抑制剂和方法 |
WO2008042688A2 (en) * | 2006-09-29 | 2008-04-10 | Lexicon Pharmaceuticals, Inc. | Phlorizin analogs as inhibitors of sodium glucose co-transporter 2 |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5753789A (en) * | 1996-07-26 | 1998-05-19 | Yale University | Oligonucleotides containing L-nucleosides |
PH12000002657B1 (en) * | 1999-10-12 | 2006-02-21 | Bristol Myers Squibb Co | C-aryl glucoside SGLT2 inhibitors |
KR100660738B1 (ko) * | 2000-03-17 | 2006-12-22 | 깃세이 야쿠힌 고교 가부시키가이샤 | 글루코피라노실록시 벤질벤젠 유도체, 그것을 함유하는의약조성물 및 그 제조중간체 |
US6683056B2 (en) * | 2000-03-30 | 2004-01-27 | Bristol-Myers Squibb Company | O-aryl glucoside SGLT2 inhibitors and method |
US6555519B2 (en) * | 2000-03-30 | 2003-04-29 | Bristol-Myers Squibb Company | O-glucosylated benzamide SGLT2 inhibitors and method |
CA2429833A1 (en) * | 2000-11-30 | 2002-06-06 | Kissei Pharmaceutical Co., Ltd. | Glucopyranosyloxybenzylbenzene derivatives, medicinal compositions containing the same and intermediates in the production thereof |
US6936590B2 (en) * | 2001-03-13 | 2005-08-30 | Bristol Myers Squibb Company | C-aryl glucoside SGLT2 inhibitors and method |
JP2004536047A (ja) * | 2001-04-11 | 2004-12-02 | ブリストル−マイヤーズ スクイブ カンパニー | 糖尿病処置用c−アリールグルコシドのアミノ酸複合体および方法 |
US6562791B1 (en) * | 2002-03-29 | 2003-05-13 | Council Of Scientific And Industrial Research | Glucopyranoside, process for isolation thereof, pharmaceutical composition containing same and use thereof |
JP2005527589A (ja) * | 2002-04-12 | 2005-09-15 | アキリオン ファーマシューティカルズ,インコーポレーテッド | β−L−5−フルオロ−2’,3’−ジデオキシ−2’,3’−ジデヒドロシチジン(β−L−FD4C)を合成するための方法 |
BR0310006A (pt) * | 2002-08-09 | 2005-02-15 | Taisho Pharmaceutical Co Ltd | Derivados de 5-tio-beta-d-glicopiranosìdeo de arila e agentes terapêuticos para diabetes contendo os mesmos |
CN101260130A (zh) | 2003-01-03 | 2008-09-10 | 布里斯托尔-迈尔斯斯奎布公司 | 制备c-芳基葡糖苷sglt2抑制剂的方法 |
US7368475B2 (en) * | 2003-03-12 | 2008-05-06 | Kemin Pharma Bvba | Furanose-type bicyclic carbohydrates with biological activity |
PL1980560T3 (pl) * | 2003-03-14 | 2011-11-30 | Astellas Pharma Inc | Pochodne C-glikozydowe do leczenia cukrzycy |
WO2006018150A1 (de) * | 2004-08-11 | 2006-02-23 | Boehringer Ingelheim International Gmbh | D-xylopyranosyl-phenyl-substituierte cyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung |
WO2006089872A1 (en) * | 2005-02-23 | 2006-08-31 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted ( (hetero)arylethynyl-benzyd-benzene derivatives and use thereof as sodium-dependent glucose cotransporter 2 (sglt2) inhibitors |
WO2008044268A1 (fr) * | 2006-10-05 | 2008-04-17 | Panasonic Corporation | Appareil et procédé de transmission |
US7846945B2 (en) * | 2007-03-08 | 2010-12-07 | Lexicon Pharmaceuticals, Inc. | Piperdine-based inhibitors of sodium glucose co-transporter 2 and methods of their use |
TWI472521B (zh) * | 2008-07-17 | 2015-02-11 | Lexicon Pharmaceuticals Inc | (2s,3r,4r,5s,6r)-2-(4-氯-3-(4-乙氧苄基)苯基)-6-(甲硫)四氫-2h-哌喃-3,4,5-三醇的固體形態與其使用方法 |
-
2008
- 2008-07-17 DK DK08826634.1T patent/DK2183263T3/da active
- 2008-07-17 ES ES08826634T patent/ES2375800T3/es active Active
- 2008-07-17 CA CA2694029A patent/CA2694029C/en active Active
- 2008-07-17 EP EP08826634A patent/EP2183263B1/en active Active
- 2008-07-17 NZ NZ582536A patent/NZ582536A/en unknown
- 2008-07-17 AT AT08826634T patent/ATE530558T1/de active
- 2008-07-17 KR KR1020107001659A patent/KR101663324B1/ko active IP Right Grant
- 2008-07-17 US US12/174,722 patent/US8026347B2/en active Active
- 2008-07-17 UA UAA201002095A patent/UA107175C2/ru unknown
- 2008-07-17 BR BRPI0813840A patent/BRPI0813840A2/pt not_active Application Discontinuation
- 2008-07-17 PT PT08826634T patent/PT2183263E/pt unknown
- 2008-07-17 CN CN200880100489.2A patent/CN101801989B/zh active Active
- 2008-07-17 EA EA201070186A patent/EA017411B1/ru not_active IP Right Cessation
- 2008-07-17 JP JP2010518296A patent/JP5653213B2/ja active Active
- 2008-07-17 PL PL08826634T patent/PL2183263T3/pl unknown
- 2008-07-17 WO PCT/US2008/070250 patent/WO2009014970A1/en active Application Filing
- 2008-07-17 AU AU2008279424A patent/AU2008279424B2/en active Active
- 2008-07-21 TW TW097127665A patent/TWI419886B/zh active
- 2008-07-21 TW TW102129521A patent/TWI506024B/zh active
- 2008-07-24 CL CL2008002169A patent/CL2008002169A1/es unknown
- 2008-07-25 AR ARP080103246A patent/AR067701A1/es active IP Right Grant
-
2010
- 2010-01-10 IL IL203209A patent/IL203209A/en active IP Right Grant
- 2010-01-12 ZA ZA2010/00219A patent/ZA201000219B/en unknown
- 2010-02-23 EC EC2010009987A patent/ECSP109987A/es unknown
- 2010-02-25 CO CO10022864A patent/CO6260141A2/es not_active Application Discontinuation
- 2010-11-12 HK HK10110567.0A patent/HK1143982A1/zh unknown
-
2011
- 2011-08-11 US US13/207,576 patent/US8293878B2/en active Active
-
2013
- 2013-08-28 JP JP2013176646A patent/JP5764174B2/ja active Active
-
2018
- 2018-08-03 AR ARP180102213 patent/AR112669A2/es active IP Right Grant
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1653075A (zh) * | 2002-05-20 | 2005-08-10 | 百时美施贵宝公司 | C-芳基葡糖苷sglt2抑制剂和方法 |
WO2008042688A2 (en) * | 2006-09-29 | 2008-04-10 | Lexicon Pharmaceuticals, Inc. | Phlorizin analogs as inhibitors of sodium glucose co-transporter 2 |
Non-Patent Citations (1)
Title |
---|
NICOLA J.DAVIS, ET AL.: "Selective Oxidation of Monosaccharide Derivatives to Uronic acids", 《TETRAHEDRON LETTERS》 * |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104854096A (zh) * | 2012-11-20 | 2015-08-19 | 莱西肯医药有限公司 | 钠葡萄糖协同转运蛋白1的抑制剂 |
CN108440614A (zh) * | 2012-11-20 | 2018-08-24 | 莱西肯医药有限公司 | 钠葡萄糖协同转运蛋白1的抑制剂 |
CN109476624A (zh) * | 2016-05-28 | 2019-03-15 | 海南轩竹医药科技有限公司 | 钠-葡萄糖协同转运蛋白2抑制剂的晶型 |
CN109476624B (zh) * | 2016-05-28 | 2021-07-09 | 吉林惠升生物制药有限公司 | 钠-葡萄糖协同转运蛋白2抑制剂的晶型 |
CN110818722A (zh) * | 2018-08-14 | 2020-02-21 | 苏州鹏旭医药科技有限公司 | 三种化合物及其制备方法和在合成索格列净中的用途 |
CN110818722B (zh) * | 2018-08-14 | 2022-12-02 | 苏州鹏旭医药科技有限公司 | 三种化合物及其制备方法和在合成索格列净中的用途 |
CN113880701A (zh) * | 2021-10-10 | 2022-01-04 | 浙江司太立制药股份有限公司 | 一种抗糖尿病药物中间体及其制备方法 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101801989B (zh) | 用于制备钠-葡萄糖协同转运蛋白2抑制剂的方法和化合物 | |
JP6283337B2 (ja) | (2s,3r,4r,5s,6r)−2−(4−クロロ−3−(4−エトキシベンジル)フェニル)−6−(メチルチオ)テトラヒドロ−2h−ピラン−3,4,5−トリオールの固体形態及びその使用方法 | |
JP4229701B2 (ja) | β−ラクタム化合物及びその製造方法並びにこれを含有する血清コレステロール低下剤 | |
AU2007245194B2 (en) | Process for preparation of HIV protease inhibitors | |
CN106928227B (zh) | 恩替卡韦的合成方法及其中间体化合物 | |
CN104114542A (zh) | 三唑并嘧啶化合物的合成 | |
JP2002536450A (ja) | エポチロン誘導体、それらの製造方法、及びそれらの医薬としての使用 | |
TWI383974B (zh) | 用於製備(3s,4s)-4-((r)-2-(苯甲氧基)十三基)-3-己基-2-氧雜環丁酮之方法以及用於該方法之新穎中間產物 | |
FR2714055A1 (fr) | Dérivés de 5-(arylalkyl)-1,3-dioxane substitués en position 2, leur préparation et leur utilisation en thérapeutique. | |
CN112375076A (zh) | 合成卡格列净的新方法 | |
CN110963955A (zh) | 一种单氟代螺环化合物的合成方法及其中间体 | |
RU2471790C1 (ru) | Способ получения (3s,4s)-4-((r)-2-(бензилокси)тридецил)-3-гексил-2-оксетанона и используемого для этого нового промежуточного соединения | |
JP2020128368A (ja) | アゾールで置換されたピリジン化合物を有効成分として含有する医薬 | |
Izquierdo et al. | Action of Base on Methyl 6-Thio-(and 6-Deoxy-) 2-O-Methanesulfonyl-α-d-Glucopyranoside Derivatives1 | |
JP2017105748A (ja) | 1,5−アンヒドロ−1−置換フェニル−d−グルシトール化合物の製造方法 | |
AU2013206276A1 (en) | Methods and compounds useful for the preparation of sodium glucose co-transporter 2 inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CI01 | Publication of corrected invention patent application |
Correction item: Ninth inventor Correct: Zhao Mangzhu Number: 32 Volume: 26 |
|
CI02 | Correction of invention patent application |
Correction item: Ninth inventor Correct: Zhao Mangzhu Number: 32 Page: The title page Volume: 26 |
|
ERR | Gazette correction |
Free format text: CORRECT: INVENTOR 9; FROM: NONE TO: ZHAO WANGZHU |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1143982 Country of ref document: HK |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1143982 Country of ref document: HK |